@article{article_1517395, title={Dimethyl Fumarate Improves Detrusor Contractility in Streptozotocin-Induced Diabetic Rats}, journal={Turkish Journal of Diabetes and Obesity}, volume={8}, pages={287–293}, year={2024}, DOI={10.25048/tudod.1517395}, author={Engin, Seçkin and Kaya Yaşar, Yeşim and Barut, Elif Nur}, keywords={Detrüsör kası, Dimetil fumarat, Diyabetik komplikasyon, Karbakol, Kasılma, Mesane, Streptozotosin}, abstract={Aim: The present study aimed to investigate potential effect of dimethyl fumarate (DMF) on bladder dysfunction in streptozotocin (STZ)-induced diabetic rats. Material and Methods: Adult male Sprague Dawley rats were given a single intraperitoneal dose of streptozotocin (60 mg/kg) to induce diabetes. After eight weeks, diabetic and nondiabetic rats were orally treated with DMF (25 or 100 mg/kg/day) or vehicle for four weeks orally. At 12 week after diabetes induction, in vitro organ bath studies were performed on detrusor strips of each rat and the contractile responses to KCl and carbachol (CCh) of the strips were evaluated. Results: The maximal KCl (80 mM)- and CCh-induced contractile responses of detrusor strips significantly (p <0.05) reduced in diabetic group (84.35±13.56 and 178.80±29.66 mg tension/mg tissue, respectively) compared to the control group (175.10±13.42 and 399.40±77.63 mg tension/mg tissue, respectively). Moreover, DMF (100 mg/kg/day for 4 weeks) restored the impaired maximal contractile responses to KCl (158.20±25.82 mg tension/mg tissue) and CCh (342.50±42.86 mg tension/mg tissue) in diabetic rats, but DMF at 25 mg/kg had no effect. Conclusion: The results of our preclinical study suggest that DMF has the potential to be repurposed as a promising therapeutic for the treatment of diabetes-associated bladder dysfunction.}, number={3}, publisher={Zonguldak Bülent Ecevit Üniversitesi}